Literature DB >> 21122030

Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension.

Afroditi K Boutou1, Georgia G Pitsiou, Ioannis Trigonis, Despina Papakosta, Paschalina K Kontou, Nikolaos Chavouzis, Chrysanthi Nakou, Paraskevi Argyropoulou, Karlman Wasserman, Ioannis Stanopoulos.   

Abstract

BACKGROUND AND
OBJECTIVE: Increased pulmonary arterial pressure (PAP) usually coexists with impaired lung function in IPF. Data on the effect of pulmonary hypertension (PH) on cardiopulmonary responses during exercise in IPF patients is very limited. We sought to investigate the impact of PH on exercise capacity and the correlation between systolic PAP (sPAP) and pulmonary function testing, as well as cardiopulmonary exercise parameters, in patients with IPF and PH.
METHODS: Eighty-one consecutive patients with IPF, who were evaluated over a 6-year period, were retrospectively studied. Patients underwent pulmonary function testing, Doppler echocardiography and maximal cardiopulmonary exercise testing. PH was defined as sPAP > 35 mm Hg.
RESULTS: PH was diagnosed in 57% of the patients. Categorization of patients according to severity of PH indicated a significant reduction in maximum work rate, peak O(2) uptake, anaerobic threshold and peak O(2) pulse in those with sPAP > 50 mm Hg. In IPF patients with PH, estimated sPAP correlated with peak O(2) uptake, anaerobic threshold, peak O(2) pulse and end-tidal CO(2) at anaerobic threshold, while the strongest correlation was between sPAP and ventilatory equivalent for CO(2) at anaerobic threshold (r = 0.611, P < 0.001). There were no differences in pulmonary function or exercise parameters indicative of lung volume reduction, across the patient categories, and none of these parameters correlated with sPAP.
CONCLUSIONS: PH has a negative impact on exercise capacity in IPF patients. In IPF patients with PH, resting sPAP correlated with exercise parameters indicative of gas exchange and circulatory impairment, but not with defective lung mechanics.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Year:  2011        PMID: 21122030     DOI: 10.1111/j.1440-1843.2010.01909.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  21 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Should we routinely screen patients with idiopathic pulmonary fibrosis for nocturnal hypoxemia?

Authors:  Georgia Pitsiou; Vasilis Bagalas; Afroditi Boutou; Ioannis Stanopoulos; Paraskevi Argyropoulou-Pataka
Journal:  Sleep Breath       Date:  2012-05-06       Impact factor: 2.816

3.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

4.  Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation.

Authors:  Hilary F Armstrong; P Christian Schulze; Matthew Bacchetta; Wilawan Thirapatarapong; Matthew N Bartels
Journal:  Respirology       Date:  2014-05-06       Impact factor: 6.424

Review 5.  New perspectives on management of idiopathic pulmonary fibrosis.

Authors:  Silvia Puglisi; Sebastiano Emanuele Torrisi; Virginia Vindigni; Riccardo Giuliano; Stefano Palmucci; Massimiliano Mulè; Carlo Vancheri
Journal:  Ther Adv Chronic Dis       Date:  2016-02-01       Impact factor: 5.091

6.  Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension?

Authors:  Kamonpun Ussavarungsi; Augustine S Lee; Charles D Burger
Journal:  Oman Med J       Date:  2016-09

7.  Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease.

Authors:  Rudolf K F Oliveira; Aaron B Waxman; Paul J Hoover; Paul F Dellaripa; David M Systrom
Journal:  Chest       Date:  2020-03-12       Impact factor: 9.410

8.  Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

Authors:  MeiLan K Han; David S Bach; Peter G Hagan; Eric Yow; Kevin R Flaherty; Galen B Toews; Kevin J Anstrom; Fernando J Martinez
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

9.  Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.

Authors:  Andrew J Bryant; Ryan P Carrick; Melinda E McConaha; Brittany R Jones; Sheila D Shay; Christy S Moore; Thomas R Blackwell; Santhi Gladson; Niki L Penner; Ankita Burman; Harikrishna Tanjore; Anna R Hemnes; Ayub K Karwandyar; Vasiliy V Polosukhin; Megha A Talati; Hui-Jia Dong; Linda A Gleaves; Erica J Carrier; Christa Gaskill; Edward W Scott; Susan M Majka; Joshua P Fessel; Volker H Haase; James D West; Timothy S Blackwell; William E Lawson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-04       Impact factor: 5.464

10.  The Impact of Pulmonary Arterial Pressure on Exercise Capacity in Mild-to-Moderate Cystic Fibrosis: A Case Control Study.

Authors:  Katerina Manika; Georgia G Pitsiou; Afroditi K Boutou; Vassilis Tsaoussis; Nikolaos Chavouzis; Marina Antoniou; Maria Fotoulaki; Ioannis Stanopoulos; Ioannis Kioumis
Journal:  Pulm Med       Date:  2012-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.